Promotion of granulation tissue formation

Promotion of granulation tissue formation refers to stimulating the development of new connective tissue and microscopic blood vessels at the site of injury during the proliferative phase of wound healing, rather than being an individual molecule, receptor, enzyme, transporter, etc. Granulation tissue consists mainly of proliferating capillaries/endothelial cells for neovascularization; fibroblasts producing extracellular matrix proteins such as type III then type I collagen; myofibroblasts responsible for contraction; and infiltrating inflammatory cells including macrophages and neutrophils. This process fills wounds with healthy vascularized connective tissue before reepithelialization occurs. The promotion—or impairment—of this process plays critical roles in clinical outcomes for chronic wounds (such as diabetic ulcers), surgical recovery, burns management, and other regenerative medicine contexts. However, because it describes a physiological event involving multiple cell types/molecules rather than one discrete molecular target suitable for direct pharmacological intervention, it should not be considered a canonical therapeutic target, but rather an endpoint/process influenced by targeting upstream effectors such as growth factors or cellular therapies.

Drugs/biologics that promote granulation tissue generally act by stimulating fibroblast proliferation and collagen synthesis; enhancing angiogenesis via growth factors like VEGF/PDGF; and modulating immune response to favor repair over inflammation.